Emergent BioSolutions Inc. (EBS) Financial Analysis & Valuation | Quarter Chart
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biolo... more
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and re... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $350.85M | Exchange | NYSE |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Joseph C. Papa Jr. |
| IPO Date | 2006-11-15 | CAGR | 12.36% |
| Employees | 900 | Website | www.emergentbiosolutions.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 3.26% | Total Yield | 3.26% |
EBS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $951.39M | P/E | 4.72 | Forward P/E | 6.5 | PEG | — |
| P/S | 1.56 | P/B | 3.2 | P/CF | 43.27 | P/FCF | 80.81 |
| Sales | $770.20M | Sales 1Y | -9.56% | Sales 3Y | -28.17% | Sales 5Y | -54.92% |
| EPS | $1.44 | EPS 1Y | -245.32% | EPS 3Y | -70.65% | EPS 5Y | -164% |
| Sales QoQ | 50.1% | EPS QoQ | -4797.17% | Sales QoQ Avg | 20.86% | EPS QoQ Avg | -1408.06% |
| Gross Margin | 49.4% | Operating Margin | -7.06% | Profit Margin | -22.96% | ROCE | -5.47% |
| ROA | -16% | ROE | -36% | Altman Z Score | 0.84 | Piotroski Score | 6 |
| Current Ratio | 5.42 | Quick Ratio | 2.95 | Cash Ratio | 1.14 | Op. CF Ratio | -0.13 |
| Debt/Equity | 1.7 | Debt/Assets | 0.52 | Lt Debt/Equity | 1.7 | Lt Debt/Cap. | 0.63 |
| Intrst Cov. | -1.07 | Inventory Turnover | 1.28 | Asset Turnover | 0.69 | Receivables Turnover | 4.05 |
| Enterprise Value | $951.39M | P/E Ratio | 4.72 |
| Forward P/E | 6.5 | PEG Ratio | — |
| P/S Ratio | 1.56 | P/B Ratio | 3.2 |
| P/CF Ratio | 43.27 | P/FCF Ratio | 80.81 |
| EPS | $1.44 | EPS Growth 1Y | -245.32% |
| EPS Growth 3Y | -70.65% | EPS Growth 5Y | -164% |
| Revenue Growth 1Y | -9.56% | Gross Margin | 49.4% |
| Operating Margin | -7.06% | Profit Margin | -22.96% |
| ROE | -36% | ROA | -16% |
| ROCE | -5.47% | Current Ratio | 5.42 |
| Quick Ratio | 2.95 | Cash Ratio | 1.14 |
| Debt/Equity | 1.7 | Interest Coverage | -1.07 |
| Altman Z Score | 0.84 | Piotroski Score | 6 |
Emergent BioSolutions Inc. (EBS) valuation & financials
Emergent BioSolutions Inc. (EBS) has a market capitalization of $350.85M and trades at a price-to-earnings ratio of 4.7. It operates in the Healthcare sector (Biotechnology).
Emergent BioSolutions Inc.'s revenue grew -9.6% over the last year.
Emergent BioSolutions Inc.'s next earnings report is scheduled for November 4, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.37. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)